M·CAM | Dr. David Martin identifies critical failings by the US Patent and Trademark Office and the Food and Drug Administration on the EpiPen case in this clip from CNBC today.

23765

post-template-default,single,single-post,postid-23765,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-4.1,wpb-js-composer js-comp-ver-6.1,vc_responsive

August 26, 2016 In Business Events, News Archive

Dr. David Martin identifies critical failings by the US Patent and Trademark Office and the Food and Drug Administration on the EpiPen case in this clip from CNBC today.

Date: Fri, 2016-08-26

Watch full video on CNBC’s website HERE

No Comments

Sorry, the comment form is closed at this time.